IncRNA SPRY4-IT1 Regulates Cell Proliferation and Migration by Sponging miR-101-3p and Regulating AMPK Expression in Gastric Cancer

Shuguang Cao, Limiao Lin, Xuanping Xia, and Hao Wu

1Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China

Increasing evidence indicates that long noncoding RNA (lncRNA) SPRY4 intrinsic transcript 1 (IncRNA SPRY4-IT1) has been reported to be associated with the progression of several cancers, but its expression level and the function of SPRY4-IT1 in the progression of gastric cancer (GC) have been rarely reported. Here we found that SPRY4-IT1 was upregulated in GC. In vitro experiments revealed that SPRY4-IT1 knockdown significantly inhibited GC cell proliferation by causing G1 arrest and promoting apoptosis, whereas SPRY4-IT1 overexpression promoted cell growth. Furthermore, functional assays indicated that SPRY4-IT1 overexpression significantly promoted cell migration and invasion. Bioinformatics analysis predicted that there is a SPRY4-IT1/miR-101-3p/AMPK axis in GC progression. A dual-luciferase reporter system validated the direct interaction of SPRY4-IT1, miR-101-3p, and AMPK. Western blot verified that the inhibition of SPRY4-IT1 decreased AMPK expression. Furthermore, silencing SPRY4-IT1 suppressed GC growth in vivo. Importantly, we demonstrated that SPRY4-IT1 overexpression was upregulated in serum exosomes from GC patients and correlated with cancer metastasis. Altogether, silencing SPRY4-IT1 suppresses the progression of GC by interacting with miR-101-3p and decreasing inhibiting AMPK expression. Taken together, our study demonstrates that SPRY4-IT1 could act as a potential therapeutic target for GC patients.

INTRODUCTION

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with East Asia accounting for more than half of the annual cases. For patients with localized GC, surgery remains the basic treatment. However, the majority of patients are diagnosed at an advanced stage, at which time radical surgery is no longer possible, and the outcome of available treatments remains unsatisfactory. Metastasis is found in more than half of advanced GC patients and causes the majority of cancer-related mortalities. Therefore, it is of great importance to find new molecular markers that will help evaluate the prognosis or develop novel therapies for GC.

Long noncoding RNA (lncRNA) is a type of noncoding RNA greater than 200 nt in length. Recent studies showed that lncRNAs can act as oncogenes or tumor suppressors in malignant tumors, suggesting that the aberrant expression of lncRNAs is associated with tumorigenesis in many types of cancers. Abnormal lncRNA expression and its association with various important clinicopathological parameters have been reported in GC. Therefore, lncRNAs may be utilized for GC diagnosis and prognosis, and they may serve as potential therapeutic targets. Recently, increasing evidence has shown that SPRY4 intronic transcript 1 (SPRY4-IT1), a lncRNA derived from an intron within the SPRY4 gene, was shown to be upregulated in various cancers. lncRNA SPRY4-IT1 is transcribed from the second intron of the SPRY4 gene and regulates the cell growth, invasion, and elevated rates of apoptosis. Knockdown of SPRY4-IT1 expression contributes to tumor invasion inhibition and elevated rates of apoptosis.

Exosomes are small membrane-derived vesicles with a diameter of approximately 30–150 nm. They play crucial roles in tumor proliferation and metastasis as mediators of cell-to-cell communication, by transferring oncogenic molecules. Studies have shown that cancer cells can secrete exosomes, and lncRNAs have been found to be enriched and stable in exosomes. However, to this day, little is known about the biological function of secreted lncRNAs in GC. In this study, we systematically analyzed the expression profiles of exosomal lncRNAs in GC patients, and we found that upregulation of plasma exosomal SPRY4-IT1 in GC was positively associated with tumor progression. Moreover, SPRY4-IT1 could function as a ceRNA to regulate the expression of AMPK by competing for miR-101-3p binding.

RESULTS

IncRNA SPRY4-IT1 Is Highly Expressed in GC Tissues and Cell Lines

To assess the role of IncRNA SPRY4-IT1 in GC, we performed qRT-PCR to examine the status of IncRNA SPRY4-IT1 expression in all GC samples and adjacent non-malignant samples. Compared with adjacent non-malignant tissues in our matched-pair study, GC tissues showed increased expression levels of IncRNA SPRY4-IT1 (p < 0.001;
Then we correlated SPRY4-IT1 levels with different clinical-pathological factors of GC tissues. We found that high SPRY4-IT1 expression was more frequently detected in GC patients with larger tumor size and advanced TNM stage (Table 1).

As shown in Figure 1B, among the three GC cell lines with various grades of differentiation, the highest expression level of SPRY4-IT1 was detected in the BGC823 cell line (poorly differentiated adenocarcinoma), while the lowest expression level of SPRY4-IT1 was detected in the MKN28 cell line (well-differentiated adenocarcinoma). Therefore, BGC823 and MKN28 cell lines were used to establish cell lines with knockdown or overexpression of SPRY4-IT1.

SPRY4-IT1 Promotes Cell Proliferation of GC In Vitro

To further examine whether SPRY4-IT1 is involved in GC progression, the small interfering RNA-SPRY4-IT1 (si-SPRY4-IT1) was transfected into the BGC823 cell line to reduce SPRY4-IT1 expression, and the pcDNA-SPRY4-IT1 was transfected into the MKN28 cell line to overexpress SPRY4-IT1. The results of the cell counting kit-8 (CCK-8) assay revealed that cell growth was significantly impaired in the BGC823 cell line transfected with si-SPRY4-IT1, whereas cell proliferation was increased in the pcDNA-SPRY4-IT1-transfected MKN28 cells (p < 0.01; Figures 1C and 1D). The colony formation assay showed that knockdown of SPRY4-IT1 significantly reduced the growth of BGC823 cells and overexpression of SPRY4-IT1 promoted cell colony-forming ability of MKN28 cells, suggesting that SPRY4-IT1 may act as an oncogene involved in the promotion of GC cell proliferation (p < 0.01; Figures 1E and 1F).

Inhibition of SPRY4-IT1 Promotes G1 Arrest and Causes Apoptosis in GC Cells In Vitro

To assess whether the pro-proliferative effects of SPRY4-IT1 on the GC cells are mediated by promoting cell cycle progression, we examined cell cycling in GC cells by flow cytometry. The results from flow cytometry showed that the suppression of SPRY4-IT1 in BGC823 cells modulated the cell cycle by inducing G0/G1 arrest when compared with the control group (p < 0.01; Figure 2A). Enhanced SPRY4-IT1 expression increased the S-phase percentage and decreased the G0/G1-phase percentage of MKN28 cells (p < 0.01; Figure 2B). Moreover, flow cytometry analysis was utilized to investigate whether apoptosis regulation is a potential contributing factor to cell growth progress induced by SPRY4-IT1. The results demonstrated that the apoptotic percentage of SPRY4-IT1-silenced BGC823 cells was obviously increased (p < 0.01; Figure 2C). As expected, the cell apoptosis was markedly decreased in MKN28 cells by pcDNA-SPRY4-IT1 (p < 0.01; Figure 2D).

SPRY4-IT1 Stimulates Migration and Invasion of GC In Vitro

We performed a transwell assay to investigate the effects of SPRY4-IT1 on migration and invasion of GC cell lines; as shown in Figures 2E and 2F, the migration and invasion of the BGC823 cell line were significantly inhibited by si-SPRY4-IT1. The pcDNA-SPRY4-IT1 was transfected into the MKN28 cell line to overexpress SPRY4-IT1. As expected, the invasion and migration of MKN28 cells were markedly increased by pcDNA-SPRY4-IT1. The results showed that
SPRY4-IT1 could strengthen the ability to initiate sphere growth in serum-free conditions but also maintain it for at least three generations (Figure 3A). Moreover, compared to the empty vector-transfected cells, expressions of cancer stem cell (CSC) markers, including CD73, CD146, and ALDH1, were significantly upregulated in the pcDNA-SPRY4-IT1-transfected cells (Figure 3B). In contrast, suppression of SPRY4-IT1 prohibited the acquisition of self-renewal in BGC823 cells, and it significantly decreased the expression of CSC markers (Figures 3C and 3D). Consistently, these experiments implicate that SPRY4-IT1 plays a role in the stem-like phenotype in GC.

SPRY4-IT1 Maintains a Stem-like Phenotype in GC In Vitro

The assessment of self-renewal in GC cell lines showed that SPRY4-IT1 expression vector-transfected MKN28 cells not only gained the ability to initiate sphere growth in serum-free conditions but also maintained it for at least three generations (Figure 3A). Moreover, compared to the empty vector-transfected cells, expressions of cancer stem cell (CSC) markers, including CD73, CD146, and ALDH1, were significantly upregulated in the pcDNA-SPRY4-IT1-transfected cells (Figure 3B). In contrast, suppression of SPRY4-IT1 prohibited the acquisition of self-renewal in BGC823 cells, and it significantly decreased the expression of CSC markers (Figures 3C and 3D). Consistently, these experiments implicate that SPRY4-IT1 plays a role in the stem-like phenotype in GC.

SPRY4-IT1 Promotes GC Tumorigenesis In Vivo

To determine whether SPRY4-IT1 could affect tumorigenesis, BGC823 cells with stable SPRY4-IT1 (sh-SPRY4-IT1) and empty vector-transfected BGC823 cells were inoculated into nude mice. Compared with the vector control, the tumors formed in the sh-SPRY4-IT1 group were dramatically smaller. Consistently, the tumor growth in the sh-SPRY4-IT1 group was significantly slower than that in the control group (p < 0.01; Figure 4A). Remarkably, the average tumor weight was obviously lower in the sh-SPRY4-IT1 group compared with the empty vector group (p < 0.01; Figure 4B). The qRT-PCR analysis of the SPRY4-IT1 expression was then performed using the xenograft tumor tissues. The results showed that the levels of SPRY4-IT1 expression in tumor tissues formed from sh-SPRY4-IT1 cells were lower than those of the tumors formed in the control group (p < 0.01; Figure 4C). These results indicate that SPRY4-IT1 is significantly associated with the proliferation of GC cells in vivo.

SPRY4-IT1 Serves as a Sponge for miR-101-3p in GC

To investigate the potential microRNAs (miRNAs) associated with SPRY4-IT1, the bioinformatics prediction analysis was performed by the miRcode online website. As shown in Figure 5A, miR-101-3p harbors a complementary binding sequence of SPRY4-IT1. We performed a luciferase reporter assay to investigate the correlation between SPRY4-IT1 and miR-101-3p. Co-transfection of pmirGLO-SPRY4-IT1-wild-type (WT) and miR-101-3p into HEK293T cells resulted in a reduction in luciferase activity compared with that from the co-transfection of pmirGLO-SPRY4-IT1-mutant (MUT) and miR-101-3p (Figure 5B). In a further RNA immunoprecipitation (RIP) experiment, SPRY4-IT1 and miR-101-3p simultaneously existed in the product precipitated by anti-AGO2 (Figure 5C), suggesting that miR-101-3p is an SPRY4-IT1-targeting miRNA. These outcomes indicated that the interaction of SPRY4-IT1 and miR-101-3p was realized by the putative binding site.

We examined the expression of miR-101-3p by qRT-PCR in GC and matched non-tumor tissue samples from 68 patients. The results of qRT-PCR showed a lower expression of miR-101-3p in cancer tissues than in matched non-tumor tissues (Figure 5D). Next, we measured the levels of miR-101-3p expression in various GC cell lines. The expression of miR-101-3p was obviously decreased in BGC823 cells, indicating the opposite result to SPRY4-IT1 expression. Subsequently, the effect of SPRY4-IT1 on miR-101-3p expression was also observed in BGC823 cells. The results manifested that miR-101-3p expression was elevated in BGC823 cells after the silencing of SPRY4-IT1 (Figure 5E). All these results suggested that SPRY4-IT1 could sponge miR-101-3p to suppress its expression.

To investigate the role of miR-101-3p on GC carcinogenesis, miR-101-3p mimics or inhibitor was transfected into GC cell lines, and the proliferation curves were performed using CCK-8 assays. Our results showed that the MKN28 cells transfected with miR-101-3p inhibitor grew at a dramatically higher rate compared with controls, whereas miR-101-3p overexpression markedly inhibited the cell growth in BGC823 cells when compared with cells transfected with miR-nc (Figures 6A and 6B). Collectively, these data indicate that miR-101-3p can inhibit GC cell proliferation, which inversely correlates with the effects of SPRY4-IT1 in GC cells.

AMPK Was a Direct Target of miR-101-3p

We searched for miR-101-3p target genes using three computer-aided miRNA target prediction programs: TargetScan, PicTar, and miRanda. We found a well-matched miR-101-3p-binding site in the 3’ UTR of AMPK in GC cells.

We performed a luciferase reporter assay to investigate the correlation between SPRY4-IT1 and miR-101-3p. Co-transfection of pmirGLO-SPRY4-IT1-wild-type (WT) and miR-101-3p into HEK293T cells resulted in a reduction in luciferase activity compared with that from the co-transfection of pmirGLO-SPRY4-IT1-mutant (MUT) and miR-101-3p (Figure 5B). In a further RNA immunoprecipitation (RIP) experiment, SPRY4-IT1 and miR-101-3p simultaneously existed in the product precipitated by anti-AGO2 (Figure 5C), suggesting that miR-101-3p is an SPRY4-IT1-targeting miRNA. These outcomes indicated that the interaction of SPRY4-IT1 and miR-101-3p was realized by the putative binding site.

We examined the expression of miR-101-3p by qRT-PCR in GC and matched non-tumor tissue samples from 68 patients. The results of qRT-PCR showed a lower expression of miR-101-3p in cancer tissues than in matched non-tumor tissues (Figure 5D). Next, we measured the levels of miR-101-3p expression in various GC cell lines. The expression of miR-101-3p was obviously decreased in BGC823 cells, indicating the opposite result to SPRY4-IT1 expression. Subsequently, the effect of SPRY4-IT1 on miR-101-3p expression was also observed in BGC823 cells. The results manifested that miR-101-3p expression was elevated in BGC823 cells after the silencing of SPRY4-IT1 (Figure 5E). All these results suggested that SPRY4-IT1 could sponge miR-101-3p to suppress its expression.

To investigate the role of miR-101-3p on GC carcinogenesis, miR-101-3p mimics or inhibitor was transfected into GC cell lines, and the proliferation curves were performed using CCK-8 assays. Our results showed that the MKN28 cells transfected with miR-101-3p inhibitor grew at a dramatically higher rate compared with controls, whereas miR-101-3p overexpression markedly inhibited the cell growth in BGC823 cells when compared with cells transfected with miR-nc (Figures 6A and 6B). Collectively, these data indicate that miR-101-3p can inhibit GC cell proliferation, which inversely correlates with the effects of SPRY4-IT1 in GC cells.

AMPK Was a Direct Target of miR-101-3p

We searched for miR-101-3p target genes using three computer-aided miRNA target prediction programs: TargetScan, PicTar, and miRanda. We found a well-matched miR-101-3p-binding site in the 3’ UTR of AMPK in GC cells.

We performed a luciferase reporter assay to investigate the correlation between SPRY4-IT1 and miR-101-3p. Co-transfection of pmirGLO-SPRY4-IT1-wild-type (WT) and miR-101-3p into HEK293T cells resulted in a reduction in luciferase activity compared with that from the co-transfection of pmirGLO-SPRY4-IT1-mutant (MUT) and miR-101-3p (Figure 5B). In a further RNA immunoprecipitation (RIP) experiment, SPRY4-IT1 and miR-101-3p simultaneously existed in the product precipitated by anti-AGO2 (Figure 5C), suggesting that miR-101-3p is an SPRY4-IT1-targeting miRNA. These outcomes indicated that the interaction of SPRY4-IT1 and miR-101-3p was realized by the putative binding site.

We examined the expression of miR-101-3p by qRT-PCR in GC and matched non-tumor tissue samples from 68 patients. The results of qRT-PCR showed a lower expression of miR-101-3p in cancer tissues than in matched non-tumor tissues (Figure 5D). Next, we measured the levels of miR-101-3p expression in various GC cell lines. The expression of miR-101-3p was obviously decreased in BGC823 cells, indicating the opposite result to SPRY4-IT1 expression. Subsequently, the effect of SPRY4-IT1 on miR-101-3p expression was also observed in BGC823 cells. The results manifested that miR-101-3p expression was elevated in BGC823 cells after the silencing of SPRY4-IT1 (Figure 5E). All these results suggested that SPRY4-IT1 could sponge miR-101-3p to suppress its expression.
SPRY4-IT1 Is Secreted by Exosomes into the Serum of GC Patients

Finally, in our current study, we collected abundant sera from 38 GC patients and 25 normal people. After the isolation of serum exosomes by sequential centrifugation, we characterized these vesicles using electron microscopy (Figure 7A). Western blot analysis confirmed the presence of four well-known exosomal markers, CD63, TSG101, Hsp 70, and Hsp 90 (Figure 7B). qRT-PCR analyses showed that SPRY4-IT1 was enriched in serum exosomes derived from GC patients (Figure 7C), implying that highly expressed SPRY4-IT1 in GC might be secreted into the tumor microenvironment, surrounded by blood vessels.

DISCUSSION

In the last few years, noncoding RNAs, including miRNAs and lncRNAs, have been demonstrated to play important roles in various human pathophysiologic processes, especially tumorigenesis.22,23 Although increasing evidence is available to clarify the mechanisms of lncRNAs in the development and progression of cancers, the knowledge remains very limited.

We herein uncover a novel carcinogenic role of SPRY4-IT1 in the development of GC. We first found that SPRY4-IT1 was significantly upregulated in GC tissues and GC cell lines. In addition, the increased expression of SPRY4-IT1 in GC patients is associated with increased tumor size and advanced TNM stage. Our subsequent studies demonstrated that SPRY4-IT1-knockdown decreased cell proliferation and migration while it promoted significant arrest in the G0/G1 phase and enhanced the apoptosis of GC cells by acting as the sponge of miR-101-3p, yet regulating the expression of AMPK. Our results unraveled that increased SPRY4-IT1 defines an important mechanism for maintaining a stem-like phenotype. Finally, we showed that overexpressed SPRY4-IT1 was secreted by exosomes into the sera of GC patients, suggesting that SPRY4-IT1 might be a novel clinical molecular marker of GC patients.

The lncRNA SPRY4-IT1 was originally identified as a 706-bp transcript present in a large-scale study involving sequencing of adipose tissue cDNA, and it was further shown to be broadly expressed in various cancers. The inhibition of SPRY4-IT1 expression causes defects in cell proliferation and differentiation and induces apoptosis in melanoma cells, suggesting that it is implicated in melanocytic transformation. In the present study, we first investigated SPRY4-IT1 expression in GC tissues and cell lines by qRT-PCR. We observed high SPRY4-IT1 expression in GC specimens. Additionally, SPRY4-IT1 expression was markedly increased in GC cell lines compared with normal gastric epithelium cells. Our results provided the first evidence that high SPRY4-IT1 expression was closely associated with GC carcinogenesis. Then we found that high SPRY4-IT1 expression was more frequently detected in GC patients with larger tumor size, deeper invasion depth, positive lymph node metastasis, and advanced
TNM stage. To explore the function of SPRY4-IT1 in GC, we performed loss-of-function experiments to test the effect of SPRY4-IT1 on GC cell lines. In addition, SPRY4-IT1 promoted GC cell proliferation and migration yet suppressed cell apoptosis, suggesting that SPRY4-IT1 might be involved in GC progression.

Accumulating evidence suggests that, as a novel class of noncoding RNAs, lncRNAs act as miRNA sponges. Based on bioinformatics analysis, it was assumed that the SPRY4-IT1/miR-101-3p/AMPK axis plays a pivotal role in GC progression. The luciferase reporter system showed that miR-101-3p targets both SPRY4-IT1 and AMPK, which provided direct evidence that SPRY4-IT1 functions as a miR-101-3p sponge to modulate AMPK expression. The cyto logical function experiment revealed that SPRY4-IT1 and miR-101-3p have reverse effects on cell phenotype. A miR-101-3p inhibitor could rescue biological changes induced by the silencing of SPRY4-IT1. Taken together, the study revealed that a SPRY4-IT1/miR-101-3p/AMPK axis exists in GC and that SPRY4-IT1 negatively regulates miR-101-3p. The aberrantly upregulated SPRY4-IT1 accompanied by downregulated miR-101-3p potentially may be used for early diagnosis and determining prognosis in GC patients.

Exosomes are membrane vesicles of an average 30- to 100-nm diameter, containing miRNA, mRNA, and proteins, and they are released by cells into the extracellular microenvironment. Recently, it has been shown that lncRNAs can be secreted by serum exosomes from cancer cells into circulation, with unknown pathological functions. Notably, we found that the highly expressed SPRY4-IT1 could be examined in the serum exosomes of GC patients.

In conclusion, our study showed that SPRY4-IT1 expression level was obviously elevated in GC tissues and cell lines and correlated with the malignant status in GC patients. Furthermore, knocking down SPRY4-IT1 expression significantly inhibited GC progression in vitro and in vivo. SPRY4-IT1 affects the proliferation and migration of GC cells by functioning as a ceRNA to regulate AMPK expression by sponging miR-101-3p.

MATERIALS AND METHODS

Clinical Tissue Samples

GC tissues and paired adjacent noncancerous tissues were obtained from 68 patients undergoing surgical procedures at The Second Affiliated Hospital and Yu Yang Children’s Hospital of Wenzhou Medical University. All patients underwent radical surgical resection. None of the patients had received preoperative radiotherapy or chemotherapy. All specimens were immediately frozen in liquid nitrogen and stored at −80°C until RNA extraction. For exosome purification, serum samples were collected from GC patients. The study was approved by the Ethical Committee of The Second Affiliated Hospital and Yu Yang Children's Hospital of Wenzhou Medical University, and it was performed in accordance with the Declaration of Helsinki (2013) of the World Medical Association. Informed consents were obtained from all patients. All of the procedures were done in accordance with the approved guidelines.

Exosome Isolation

Exosome extraction was performed essentially as described before. Briefly, 48 h after irradiation, the medium was decanted, centrifuged at 2,000 × g for 10 min to sediment cells, and then centrifuged at 10,000 × g for 30 min to deplete cell debris. Exosomes were further isolated by ultracentrifugation at 120,000 × g for 60 min, and the pellets were re-suspended using PBS. After another two repeats, the exosomes were stored in liquid nitrogen.
were finally re-suspended in PBS and stored at −70°C for use. The concentration of exosomes was determined using the BCA method, as recommended by the manufacturer (Thermo Scientific, USA).

Transmission Electron Microscopy (TEM)
Brieﬂy, the exosome suspension was added to an equal volume of 4% paraformaldehyde and applied to a Formvar/carbon ﬁlm-coated transmission electron microscope grid (Alliance Biosystems, Osaka, Japan). Subsequently, samples was ﬁxed by incubation with 1% glutaraldehyde, washed with PBS, contrasted with 1% uranyl acetate, embedded in epoxy resin, and polymerized. Exosomes were subsequently observed under a Hitachi H-7650 transmission electron microscope (Hitachi, Tokyo, Japan).

Western Blotting
To identify exosome markers, primary antibodies against CD63 and TSG101 were purchased from Abcam (Cambridge, UK), and primary antibodies against Hsp 70 and Hsp 90 were obtained from Cell Signaling Technology (Beverly, MA, USA). The secondary antibodies were F(ab)2 fragments of donkey anti-mouse immunoglobulin or donkey anti-rabbit immunoglobulin linked to horseradish peroxidase (Jackson ImmunoResearch Laboratories, USA). Immunoblotting reagents from an electrochemiluminescence kit were used (Amersham Biosciences, Uppsala, Sweden).

Cell Lines and Transfection
The normal gastric mucosa epithelial GES-1 cell line and three different differentiated GC cell lines, MKN28 (well-differentiated adenocarcinoma), SGC7901 (moderately differentiated adenocarcinoma), and BGC823 (poorly differentiated adenocarcinoma), were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cell lines were cultured in RPMI 1640 medium (Gibco, USA), containing 10% fetal bovine serum (FBS) (Gibco, USA), 100 U/mL penicillin, and 100 mg/mL streptomycin, at 37°C.

The si-SPRY4-IT1 or pcDNA- SPRY4-IT1 was transfected into cells using Lipofectamine 2000 Reagent (Thermo Fisher Scientific, USA) in a 6-well cell culture plate, following the the manufacturer’s instructions. Transfection with an si-control or empty pcDNA served as the negative control. At 24 h after incubating, the cells were harvested and we performed the following experiments. Real-time PCR was used to detect the expression of SPRY4-IT1 and confirm the transfection efﬁciency. Small interfering RNAs (siRNAs) were synthesized by Guangzhou RiboBio (Guangzhou, China), and pcDNA plasmids were prepared by Life Technologies (Beijing, China).

RNA Isolation and qRT-PCR
The total RNA was isolated from tissues and cell lines using TRIzol reagent (Invitrogen, CA, USA), and exosomal RNA was extracted from plasma and culture medium using the exoRNeasy Midi Kit (QIAGEN, Valencia, CA, USA), according to the manufacturer’s protocol.

The cDNA was synthesized using a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Vilnius, Lithuania). Real-time qPCR was conducted with an ABI 7900 system (Applied Biosystems, CA, USA) and SYBR Green assays (TaKaRa Biotechnology, Dalian, China). We chose glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to normalize lncRNA expression levels. The fold change in the expression of lncRNA was calculated with the formula $2^{-\Delta\Delta CT}$. The sequences of the primers were as follows: SPRY4-IT1 forward, 5'-AGCCACATAAATTCAGCAGA-3'; reverse, 5'-CGATG TAGTAGTAGTTTCTTTTTCA-3'; and GAPDH forward, 5'-GACTCA TGACCACAGTCCATGC-3'; reverse, 5'-AGAGGCAAGGGATGAGT GCTTG-3'. An ABI 7500 was used to carry out the qPCR and data collections.

Colony Formation Assay and CCK-8 Assay
Cells were plated in 6-well plates (2 × 10^3 cells/well). The number of colonies (>50 cells per colony) was counted after staining with Giemsa 14 days later, and the colonies were photographed. Each experiment was performed in triplicate three times. A CCK-8 (Beyotime, China) was employed to quantitatively evaluate cell viability. Brieﬂy, 2 × 10^3 cells/well were seeded in 96-well ﬂat-bottomed plates, then grown at 37°C for 24, 48, and 72 h. Then, the original medium in
each well was replaced by 200 μL 10% FBS/RPMI 1640 medium containing 20 μL CCK-8. The cells were incubated at 37°C for 2 h, and the absorbance was determined at wavelengths of 450 and 630 nm (calibrated wave) using a microplate reader. RPMI 1640 containing 10% CCK-8 was used as a control.

**Transwell Assay**

The migration and invasion of cells were assessed based on transwell chambers with a pore size of 0.8 μm and the number of cells through Matrigel-coated transwell inserts. A total of 1 × 10^5 cells was seeded in serum-free medium in the upper chamber, while medium containing 10% FBS was added as a chemoattractant to the lower chamber, thus serving as a chemoattractant. For the invasion assay, cells were seeded into 24-well plate-sized inserts with Matrigel (BD Biosciences, San Jose, CA, USA). After incubating for 48 h at 37°C, the cells in the upper chamber were carefully removed with a cotton swab, and the cells that had migrated or invaded to the reverse face of the membrane. The cells located on the lower surfaces were fixed with 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 15 min at room temperature. The assay was conducted three separate times.

**Tumorsphere Assay**

Single cell was seeded on ultra-low attachment plates (Corning, Corning, NY, USA) at a concentration of 3,000 cells/mL in medium (Invitrogen, Carlsbad, CA, USA) supplemented with B27 (1:50; Gibco, Grand Island, NY, USA), 20 ng/mL epidermal growth factor (EGF) (PeproTech, Rocky Hill, NJ, USA), and 10 ng/mL basic fibroblast growth factor (FGF) (PeproTech). Tumorspheres 450 μm in diameter were counted 7 days after seeding. The first generations of 10-day-old spheres were collected by gravity and dissociated to single-cell suspension with trypsin for serial passaging (G1–G3).

**Flow Cytometry Analysis**

For flow cytometry analysis, cells were fixed in 70% ethanol for 30 min at 4°C and incubated with CD73 (fluorescein isothiocyanate [FITC]) and CD146 (FITC) (BD Pharmingen, San Diego, CA) supplemented with B27 (1:50; Gibco, Grand Island, NY, USA), 20 ng/mL epidermal growth factor (EGF) (PeproTech, Rocky Hill, NJ, USA), and 10 ng/mL basic fibroblast growth factor (FGF) (PeproTech). Tumorspheres 450 μm in diameter were counted 7 days after seeding. The first generations of 10-day-old spheres were collected by gravity and dissociated to single-cell suspension with trypsin for serial passaging (G1–G3).

**Figure 5. SPRY4-IT1 Serves as a Sponge for miR-101-3p in GC**

(A) StarBase version (v.)2.0 results showing the sequence of SPRY4-IT1 with highly conserved putative miR-101-3p-binding sites. (B) miR-101-3p mimics considerably reduced the luciferase activity of the WT-SPRY4-IT1 luciferase reporter vector compared with negative control, while SPRY4-IT1 mimics did not have any impact on the luciferase activity of MUT-SPRY4-IT1-transfected cells. (C) SPRY4-IT1 and miR-101-3p simultaneously existed in the production precipitated by anti-AGO2. (D) The level of miR-101-3p was significantly decreased in GC tissues as compared to that in matched non-tumor tissues. (E) Silencing of SPRY4-IT1 increased the expression level of miR-101-3p in BGC823 cells. All tests were performed at least three times. Data were expressed as mean ± SD. **p < 0.01.
at a concentration of $1 \times 10^7$ cells/0.2 mL. Each mouse was inoculated subcutaneously in the right flank with cells stably transduced with sh-SPRY4-IT1 or sh-NC. Tumor size was monitored every 3 days, and mice were euthanized after 4 weeks. All experimental procedures took place at the animal center of Wenzhou Medical University, and they were approved by the Animal Ethics Committee of Wenzhou Medical University; animal experiments were performed following the NIH Guide for the Care and Use of Laboratory Animals.

**Luciferase Reporter Assay**

HEK293T cells ($5 \times 10^3$) were seeded into 96-well plates and co-transfected with corresponding plasmids and microRNA mimics or inhibitors using the Lipofectamine 2000 transfection reagent. Luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Madison, WI, USA) after 48 h of incubation, according to the manufacturer’s instructions. Independent experiments were performed in triplicate. Relative luciferase activity was normalized to the Renilla luciferase internal control.

**Figure 6. AMPK Was a Direct Target of miR-101-3p**

(A) The CCK-8 assay showed that MKN28 cells transfected with miR-101-3p inhibitor grew at a dramatically higher rate as compared with controls. (B) CCK-8 assay showed that miR-101-3p overexpression markedly inhibits the cell growth of BGC823 cells when compared with cells transfected with miR-nc. Error bars represent mean ± SD from three independent experiments. **p < 0.01. (C) miR-101-3p is highly conserved across species and binding sites within the seed region sequence in the 3′ UTR of AMPK. (D) Luciferase assay in HEK293 cells. pmirGLO-AMPK-WT or pmirGLO-AMPK-MUT vector was co-transfected with miR-101-3p vector. Luciferase activity in pmirGLO-AMPK-WT group denoted a statistically significant decrease following ectopic expression of miR-101-3p. (E) Transfection of the miR-101-3p inhibitor increased the expression of AMPK in BGC823 cells. All tests were performed at least three times. Data were expressed as mean ± SD. **p < 0.01.

**Figure 7. SPRY4-IT1 Was Secreted into Exosomes Derived from the Sera of GC Patients**

(A) Representative image of an exosome (indicated by red arrows) derived from the sera of GC patients as detected from an electron microscope. (B) Western blotting analysis of the exosomal markers CD63, TSG101, Hsp 70, and Hsp 90 in an exosome. (C) qRT-PCR for the abundance of SPRY4-IT1 in serum exosomes. The levels of SPRY4-IT1 in serum exosomes from GC patients were significantly higher than those in normal individuals. Data were expressed as mean ± SD. **p < 0.01.
RIP Assay
RIP assay was performed using an EZ-Magna RIP Kit (Millipore, Billerica, MA, USA), in accordance with the manufacturer’s instructions. Cells were lysed at 70%–80% confluence in RIP lysis buffer, and then they were incubated with magnetic beads conjugated with human anti-Ago2 antibody (Millipore) and normal mouse immunoglobulin G (IgG) control (Millipore) in RIP buffer. The RNAs in the immuno-precipitates were isolated with Trizol reagent and analyzed by qRT-PCR.

Immunohistochemistry
For each patient sample, three paraffin sections of 5 μm were prepared, one for H&E staining and the other two for immunohistochemical staining. PBS instead of primary antibodies was used for the negative control, and the breast cancer tissue was used for the positive control. Sections were dewaxed using xylene, followed by hydration with ethanol solutions and the addition of EDTA for antigen retrieval. Later, sections were blocked with normal goat serum for 15 min to eliminate non-specific binding. Sections were incubated with anti-human AMPK polyclonal antibody (1:1,000; Abcam, Cambridge, MA, USA). Sections were then incubated with biotin-labeled secondary antibodies for 30 min at room temperature, followed by staining with diaminobenzidine (DAB). Finally, the sections were counterstained with hematoxylin. The results of staining were determined by two doctors who did not know the clinical condition of patients. The proportions of positive cells of 0%, 1%–5%, 6%–25%, 26%–75%, and 76%–100% were assigned with scores of 0, 1, 2, 3, and 4, respectively. Scores of 0–2 were considered as negative expression, and scores of 3–4 were considered as positive expression.

Statistical Analysis
All statistical analyses were performed using the SPSS 17.0 software package (SPSS, Chicago, IL, USA). The significance of differences between groups was estimated by the Student’s t test and chi-square test. The results are reported as the means ± SDs. Statistical significance was assigned at p < 0.05 (*) or p < 0.01 (**). All experiments were performed at least three times with triplicate samples.

REFERENCES
1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386.
2. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917.
3. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014). Cancer statistics. 2014. CA Cancer J. Clin. 64, 9–29.
4. Peng, P., Wu, W., Zhao, J., Song, S., Wang, X., Jia, D., Shao, M., Zhang, M., Li, L., Wang, L., et al. (2016). Decreased expression of Calpain-9 predicts unfavorable prognosis in patients with gastric cancer. Sci. Rep. 6, 29604.
5. Kong, P., Wu, R., Yang, C., Geng, Q., Liu, J., Chen, S., Liu, X., Ye, M., He, W., Yang, Q., et al. (2016). Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer. Sci. Rep. 6, 26313.
6. Kornienko, A.E., Guenzl, P.M., Barlow, D.P., and Pauler, F.M. (2015). Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 11, 59.
7. Ponting, C.P., Oliver, P.L., and Reik, W. (2009). Evolution and functions of long noncoding RNAs. Cell 136, 629–641.
8. Xu, X.F., Li, J., Cao, Y.X., Chen, D.W., Zhang, Z.G., He, X.J., Ji, D.M., and Chen, B.L. (2015). Differential Expression of Long Noncoding RNAs in Human Cumulus Cells Related to Embryo Developmental Potential: A Microarray Analysis. Reprod. Sci. 22, 672–678.
9. Chalei, V., Sansom, S.N., Kong, L., Lee, S., Montiel, J.F., Vance, K.W., and Ponting, C.P. (2014). The long non-coding RNA Dali is an epigenetic regulator of neural differentiation. eLife 3, e04530.
10. Taft, R.J., Pang, K.C., Mercer, T.R., Dinger, M., and Mattick, J.S. (2010). Non-coding RNAs: regulators of disease. J. Pathol. 220, 126–139.
11. Zhang, Z.Z., Zhao, G., Zhuang, C., Shen, Y.Y., Zhao, W.Y., Xu, J., Wang, M., Wang, C.J., Tu, L., Cao, H., and Zhang, Z.G. (2016). Long non-coding RNA LINCO00628 functions as a gastric cancer suppressor via long-range modulating the expression of cell cycle related genes. Sci. Rep. 6, 27435.
12. Sun, T.T., He, J., Liang, Q., Ren, L.L., Yan, T.T., Yu, T.C., Tang, J.Y., Bao, Y.J., Hu, Y., Lin, Y., et al. (2016). IncRNA G Clint1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer Discov. 6, 784–801.
13. Mazur, J., Zhao, W., Khalil, A.M., Lee, B., Shelley, J., Govindarajan, S.S., Yamamoto, F., Ratnam, M., Alfah, M.N., Collins, S., et al. (2014). The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget 5, 8859–8969.
14. Peng, W., Wu, G., Fan, H., Wu, J., and Feng, J. (2015). Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour Biol. 36, 6751–6758.
15. Shi, Y., Li, J., Liu, Y., Ding, J., Fan, Y., Tian, Y., Wang, L., Lian, Y., Wang, K., and Shu, Y. (2015). The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol. Cancer 14, 51.
16. Xie, H.W., Wu, Q.Q., Zhu, B., Chen, F.J., Ji, L., Li, S.Q., Wang, C.M., Tong, Y.S., Tou, L., Wu, M., et al. (2014). Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol. 35, 7743–7754.
17. Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., and Xu, W. (2015). Exomes in cancer: small particle, big player. J. Hematol. Oncol. 8, 83.
18. Santangelo, L., Giurato, G., Cicchini, C., Montaldo, C., Mancone, C., Tarallo, R., Battiostelli, C., Alonzi, T., Weiss, A., and Tripodi, M. (2016). The RNA-binding protein SYNCRIP is a component of the hepatocytic exosomal machinery controlling microRNA sorting. Cell Rep. 17, 799–808.
19. Beckham, C.J., Olsen, J., Yin, P.N., Wu, C.H., Ting, H.J., Hagen, F.K., Sossyev, E., Messing, E.M., and Lee, Y.F. (2014). Bladder cancer exosomes contain EDIL-3 and facilitate cancer progression. J. Urol. 192, 583–592.
20. Bae, S., Brumbaugh, J., and Bonavides, B. (2018). Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment. Genes Cancer 9, 87–100.
21. Li, Y., Zheng, Q., Bao, C., Li, S., Guo, W., Zhao, J., Chen, D., Gu, J., He, X., and Huang, S. (2015). Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 25, 981–984.
22. Harries, L.W. (2012). Long non-coding RNAs and human disease. Biochem. Soc. Trans. 40, 902–906.
23. Kung, J.T., Colognori, D., and Lee, J.T. (2013). Long noncoding RNAs: past, present, and future. Genetics 193, 651–669.

24. Lin, P., Wen, D.Y., Li, Q., He, Y., Yang, H., and Chen, G. (2018). Genome-Wide Analysis of Prognostic IncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma. Cell. Physiol. Biochem. 48, 1953–1967.

25. Pan, B.T., Teng, K., Wu, C., Adam, M., and Johnstone, R.M. (1985). Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101, 942–948.

26. Muller, L., Mitsuhashi, M., Simms, P., Gooding, W.E., and Whiteside, T.L. (2016). Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci. Rep. 6, 20254.